EndoResFellow said:The GIP arm is doing real work rather than padding the label.
True, though the ladder is longer and that is not a neutral detail — six dose steps means six opportunities to stall on the way up, and plenty of people never reach the dose the headline number came from.
Correct me if the detail matters more than I have assumed.
amy_econ_NJ said:Agreed on adaptation, with a caveat: adaptation applies to gastric emptying and not to everything.
Bookmarking. The distinction being drawn above is the one nobody else makes.
EndoResFellow said:The GIP arm is doing real work rather than padding the label.
Pushing back on EndoResFellow here. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsThe figures, for anyone assembling their own picture. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.
Moderator note: the sourcing question belongs in the vendor section and has been split out. Thread quality here is what the rules are for. Keep it up.